Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2018-19 | Page 91

# Consolidated Statement of Cash Flows

**Reporting Period:** For the Year ended June 30, 2019  
**Reporting Currency & Multiplier:** BDT (Amount in Taka) | **Scale Multiplier:** 1

### Consolidated Statement of Cash Flows

| Particulars | Notes | July 2018-June 2019 | July 2017-June 2018 |
| --- | --- | --- | --- |
| Cash Flows from Operating Activities : |  |  |  |
| Receipts from Customers and Others |  | 22,463,550,299 | 17,195,399,333 |
| Payments to Suppliers and Employees |  | (17,434,690,241) | (14,113,012,465) |
| Cash Generated from Operations |  | 5,028,860,058 | 3,082,386,868 |
| Interest Paid |  | (1,032,409,014) | (536,570,775) |
| Interest Received |  | 36,457,527 | 54,928,425 |
| Income Tax Paid |  | (1,072,991,667) | (781,630,595) |
| Net Cash Generated from Operating Activities | 35 | 2,959,916,904 | 1,819,113,923 |
| Cash Flows from Investing Activities : |  |  |  |
| Acquisition of Property, Plant and Equipment |  | (4,416,446,385) | (4,951,352,340) |
| Intangible Assets |  | (128,619,282) | (106,921,036) |
| Investment in Subsidiary |  | - | (2,125,186,000) |
| Disposal of Property, Plant and Equipment |  | 17,540,625 | 14,114,722 |
| Dividend Received |  | 1,491,901 | 1,504,092 |
| Decrease in Short Term Investment |  | 16,032,638 | 547,179,732 |
| Net Cash Used in Investing Activities |  | (4,510,000,503) | (6,620,660,830) |
| Cash Flows from Financing Activities : |  |  |  |
| Net Increase /(Decrease) in Long Term Borrowings |  | (1,412,334,115) | 1,859,021,877 |
| Net Increase in Short Term Borrowings |  | 3,684,312,230 | 3,546,896,539 |
| Share capital |  | 100 | - |
| Dividend Paid |  | (505,351,881) | (502,757,959) |
| Net Cash Generated from Financing Activities |  | 1,766,626,334 | 4,903,160,457 |
| Increase in Cash and Cash Equivalents |  | 216,542,735 | 101,613,550 |
| Cash and Cash Equivalents at Beginning of Year | 14 | 393,735,946 | 292,122,396 |
| Effect of exchange rate changes on Cash and Cash Equivalents |  | 215,618 | - |
| Cash and Cash Equivalents at End of Year |  | 610,494,299 | 393,735,946 |
| Net Operating Cash Flow Per Share | 34 | 7.30 | 4.49 |